Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Personalized molecular reprogramming of the tumor immune microenvironment and engineered adoptive cell transfer in synergy with ion-beam radiotherapy for next-generation curative cancer treatments

Obiettivo

Cancer is a complex multifaceted disease. To conquer cancer, a multidisciplinary approach for rational design of multimodal therapies is imperative. Ground-breaking discoveries in immunotherapy and precision radiotherapy (RT) coupled with initial encouraging results of their combined application, have engendered hope that curative cancer treatments may become possible. Our objective is to harness the full synergistic potential of both modalities through deeper comprehension of the tumor immune microenvironment (TIME) evolution in response to therapy selection pressures. We propose innovative strategies to overcome five major obstacles limiting immunotherapy success: i) tumor camouflage from immune cell recognition, ii) limited immune cell homing and tumor trafficking, iii) paucity of immune activating signals, iv) suppressive signals in the TIME, and v) failure to induce deep memory responses for durable antitumor immunity. The convergence of four research fields, each represented by pioneering scientists, provides a unique opportunity to revolutionize current cancer treatment. To reprogram TIME and create an immunopermissive tumor niche we will employ a broad spectrum of clinical-grade ion beams including protons, helium-, carbon-, and oxygen ions with unique biophysical properties. These novel beam qualities, combined with targeted molecular countermeasures against key tumor immune evasive mechanisms, such as interference with TGFbeta- and integrated stress response pathways, will establish an effective in situ cancer vaccination strategy. In synergy with RT-mediated TIME reprogramming, two adoptive immune cell therapies will be explored: personalized vaccine-induced T cells targeting tumor-specific intracellular neoantigens and chimeric antigen receptor (CAR) T cells engineered to specifically recognize tumor membrane-associated antigens. Our team is uniquely positioned worldwide to develop the next generation of precision immunoradiotherapy.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-SYG - HORIZON ERC Synergy Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2025-SyG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

UNIVERSITATSKLINIKUM HEIDELBERG
Contributo netto dell'UE
€ 4 325 147,75
Indirizzo
IM NEUENHEIMER FELD 672
69120 HEIDELBERG
Germania
Regione
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 4 325 147,75

Beneficiari (4)